SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Medical ImagingNuclear Medical

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2146292

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 2146292

Radiopharmaceutical Preclinical CRO Market Outlook, Growth Drivers and Opportunities, 2026-2033

PUBLISHED:
PAGES: 288 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

Radiopharmaceutical Preclinical CRO Market Projected to Reach US$1.12 Bn by 2033

Introduction

The global radiopharmaceutical preclinical cro market is valued at US$0.49 Bn in 2026 and projected to reach US$1.12 Bn by 2033, at a CAGR of 12.6% during 2026-2033. Fairfield Market Research assesses the market through its published product, customer and geographical classifications. The forecast provides a common basis for evaluating commercial priorities across the study period.

Market Insights

The service type breakdown covers Radiolabeling and Radiochemistry, Preclinical Imaging, In Vivo Pharmacokinetics and Biodistribution, Dosimetry and Radiation Safety and Toxicology and IND-Enabling Studies. The isotope type breakdown covers Beta Emitters, Alpha Emitters, Diagnostic Positron and Gamma Emitters and Others. The application breakdown covers Oncology, Neurology, Cardiology, Infectious and Inflammatory Disease and Others. These distinctions help businesses assess which offerings and customer requirements fall within the market's scope. The global forecast should be read alongside these segment definitions rather than applied uniformly to every individual category.

Within the service type classification, Radiolabeling and Radiochemistry and Preclinical Imaging represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Within the isotope type classification, Beta Emitters and Alpha Emitters represent separate categories in the report. Keeping these categories distinct helps readers evaluate the fit of an offering before applying the overall market forecast to a specific commercial plan.

Drivers

Fairfield's growth discussion addresses protein, distribution, quality and safety. These themes provide a starting point for assessing demand conditions and the requirements facing suppliers. Their commercial importance depends on the segment, customer and region concerned. Businesses can use the report's detailed discussion to connect these demand factors with their own portfolios and sales priorities.

Business Opportunity

The opportunity discussion highlights manufacturing, cost, distribution and safety. Companies evaluating expansion can compare these areas with their existing capabilities, route to market and customer needs. Segment selection and regional positioning remain central to assessing the relevance of the published forecast to an individual business.

Businesses considering Radiolabeling and Radiochemistry can compare its customer requirements with those associated with Preclinical Imaging. This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Businesses considering Beta Emitters can compare its customer requirements with those associated with Alpha Emitters. This comparison can help define a more focused portfolio, identify the appropriate sales audience and establish which questions require additional segment evidence before resources are committed.

Region Analysis

North America is identified in Fairfield's regional analysis as a leading market. The geographical scope covers North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Regional comparisons should use the report's own market definitions and forecast period.

Key Players

  • Charles River Laboratories
  • Labcorp
  • Inotiv
  • Invicro
  • Evotec
  • Pharmaron
  • WuXi AppTec
  • Eckert & Ziegler
  • Crown Bioscience
  • SOFIE
  • Symeres
  • Selvita
  • Nuvisan
  • Shin Nippon Biomedical Laboratories
  • ABX advanced biochemical compounds
  • Molecular Targeting Technologies
  • Nuclear Research and Consultancy Group
  • Quotient Sciences
  • Nucleus RadioPharma
  • ITM Isotope Technologies Munich

Segmentation

By Service Type

  • Radiolabeling and Radiochemistry
  • Preclinical Imaging
  • In Vivo Pharmacokinetics and Biodistribution
  • Dosimetry and Radiation Safety
  • Toxicology and IND-Enabling Studies

By Isotope Type

  • Beta Emitters
  • Alpha Emitters
  • Diagnostic Positron and Gamma Emitters
  • Others

By Application

  • Oncology
  • Neurology
  • Cardiology
  • Infectious and Inflammatory Disease
  • Others

By End User

  • Pharmaceutical and Biotechnology Companies
  • Emerging Radiopharmaceutical Biotechs
  • Academic and Research Institutes
  • Government and Nuclear Research Organizations

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Market Snapshot
  • 1.2. Market Size and Trend Analysis 2026-2033
  • 1.3. Key Industry Highlights

2. Market Overview

  • 2.1. Market Definition and Segmentation
  • 2.2. Market Dynamics
    • 2.2.1. Market Growth Drivers
      • 2.2.1.1. Targeted Radioligand Therapy Pipelines Are Pushing Work Outward
      • 2.2.1.2. Regulatory Expectations for Dosimetry Are Raising Study Volumes
    • 2.2.2. Restraints Impact Analysis of Market
      • 2.2.2.1. Isotope Supply and Short Half-Lives Constrain Study Scheduling
      • 2.2.2.2. Licensing, Capital Cost and Scarce Radiochemistry Talent Limit Capacity
    • 2.2.3. Market Opportunities
      • 2.2.3.1. Integrated Discovery-to-IND Packages Create Higher-Value Mandates
      • 2.2.3.2. Alpha Therapy and Non-Oncology Tracers Open New Service Lines
  • 2.3. Category-wise Insights
    • 2.3.1. Radiochemistry Holds the Core While Dosimetry Grows Fastest
    • 2.3.2. Which Isotope Class Anchors Preclinical Radiopharmaceutical Programmes?
    • 2.3.3. Oncology Dominates Spending While Neurology Scales Quickly
    • 2.3.4. Pharmaceutical Sponsors Lead as Emerging Biotechs Accelerate

3. Global Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 3.1. Global Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 3.1.1. Radiolabeling and Radiochemistry
    • 3.1.2. Preclinical Imaging
    • 3.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 3.1.4. Dosimetry and Radiation Safety
    • 3.1.5. Toxicology and IND-Enabling Studies
  • 3.2. Global Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 3.2.1. Beta Emitters
    • 3.2.2. Alpha Emitters
    • 3.2.3. Diagnostic Positron and Gamma Emitters
    • 3.2.4. Others
  • 3.3. Global Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 3.3.1. Oncology
    • 3.3.2. Neurology
    • 3.3.3. Cardiology
    • 3.3.4. Infectious and Inflammatory Disease
    • 3.3.5. Others
  • 3.4. Global Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 3.4.1. Pharmaceutical and Biotechnology Companies
    • 3.4.2. Emerging Radiopharmaceutical Biotechs
    • 3.4.3. Academic and Research Institutes
    • 3.4.4. Government and Nuclear Research Organizations
  • 3.5. Global Radiopharmaceutical Preclinical CRO Market Outlook, by Region, Value (US$ Billion), 2026-2033
    • 3.5.1. North America
    • 3.5.2. Europe
    • 3.5.3. Asia Pacific
    • 3.5.4. Latin America
    • 3.5.5. Middle East & Africa

4. North America Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 4.1. North America Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 4.1.1. Radiolabeling and Radiochemistry
    • 4.1.2. Preclinical Imaging
    • 4.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 4.1.4. Dosimetry and Radiation Safety
    • 4.1.5. Toxicology and IND-Enabling Studies
  • 4.2. North America Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 4.2.1. Beta Emitters
    • 4.2.2. Alpha Emitters
    • 4.2.3. Diagnostic Positron and Gamma Emitters
    • 4.2.4. Others
  • 4.3. North America Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 4.3.1. Oncology
    • 4.3.2. Neurology
    • 4.3.3. Cardiology
    • 4.3.4. Infectious and Inflammatory Disease
    • 4.3.5. Others
  • 4.4. North America Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 4.4.1. Pharmaceutical and Biotechnology Companies
    • 4.4.2. Emerging Radiopharmaceutical Biotechs
    • 4.4.3. Academic and Research Institutes
    • 4.4.4. Government and Nuclear Research Organizations
  • 4.5. North America Radiopharmaceutical Preclinical CRO Market Outlook, by Country and Subregion, 2026-2033
    • 4.5.1. United States Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 4.5.2. United States Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 4.5.3. United States Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 4.5.4. United States Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 4.5.5. Canada Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 4.5.6. Canada Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 4.5.7. Canada Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 4.5.8. Canada Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033

5. Europe Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 5.1. Europe Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 5.1.1. Radiolabeling and Radiochemistry
    • 5.1.2. Preclinical Imaging
    • 5.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 5.1.4. Dosimetry and Radiation Safety
    • 5.1.5. Toxicology and IND-Enabling Studies
  • 5.2. Europe Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 5.2.1. Beta Emitters
    • 5.2.2. Alpha Emitters
    • 5.2.3. Diagnostic Positron and Gamma Emitters
    • 5.2.4. Others
  • 5.3. Europe Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 5.3.1. Oncology
    • 5.3.2. Neurology
    • 5.3.3. Cardiology
    • 5.3.4. Infectious and Inflammatory Disease
    • 5.3.5. Others
  • 5.4. Europe Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 5.4.1. Pharmaceutical and Biotechnology Companies
    • 5.4.2. Emerging Radiopharmaceutical Biotechs
    • 5.4.3. Academic and Research Institutes
    • 5.4.4. Government and Nuclear Research Organizations
  • 5.5. Europe Radiopharmaceutical Preclinical CRO Market Outlook, by Country and Subregion, 2026-2033
    • 5.5.1. Netherlands Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.2. Netherlands Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.3. Netherlands Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.4. Netherlands Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.5. Belgium Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.6. Belgium Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.7. Belgium Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.8. Belgium Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.9. France Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.10. France Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.11. France Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.12. France Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.13. Poland Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.14. Poland Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.15. Poland Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.16. Poland Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.17. Germany Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.18. Germany Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.19. Germany Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.20. Germany Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.21. United Kingdom Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.22. United Kingdom Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.23. United Kingdom Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.24. United Kingdom Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 5.5.25. Austria Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 5.5.26. Austria Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 5.5.27. Austria Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 5.5.28. Austria Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033

6. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 6.1. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 6.1.1. Radiolabeling and Radiochemistry
    • 6.1.2. Preclinical Imaging
    • 6.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 6.1.4. Dosimetry and Radiation Safety
    • 6.1.5. Toxicology and IND-Enabling Studies
  • 6.2. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 6.2.1. Beta Emitters
    • 6.2.2. Alpha Emitters
    • 6.2.3. Diagnostic Positron and Gamma Emitters
    • 6.2.4. Others
  • 6.3. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 6.3.1. Oncology
    • 6.3.2. Neurology
    • 6.3.3. Cardiology
    • 6.3.4. Infectious and Inflammatory Disease
    • 6.3.5. Others
  • 6.4. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 6.4.1. Pharmaceutical and Biotechnology Companies
    • 6.4.2. Emerging Radiopharmaceutical Biotechs
    • 6.4.3. Academic and Research Institutes
    • 6.4.4. Government and Nuclear Research Organizations
  • 6.5. Asia Pacific Radiopharmaceutical Preclinical CRO Market Outlook, by Country and Subregion, 2026-2033
    • 6.5.1. China Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 6.5.2. China Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 6.5.3. China Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 6.5.4. China Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 6.5.5. Japan Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 6.5.6. Japan Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 6.5.7. Japan Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 6.5.8. Japan Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 6.5.9. South Korea Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 6.5.10. South Korea Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 6.5.11. South Korea Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 6.5.12. South Korea Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 6.5.13. India Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 6.5.14. India Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 6.5.15. India Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 6.5.16. India Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 6.5.17. Australia Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 6.5.18. Australia Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 6.5.19. Australia Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 6.5.20. Australia Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033

7. Latin America Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 7.1. Latin America Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 7.1.1. Radiolabeling and Radiochemistry
    • 7.1.2. Preclinical Imaging
    • 7.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 7.1.4. Dosimetry and Radiation Safety
    • 7.1.5. Toxicology and IND-Enabling Studies
  • 7.2. Latin America Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 7.2.1. Beta Emitters
    • 7.2.2. Alpha Emitters
    • 7.2.3. Diagnostic Positron and Gamma Emitters
    • 7.2.4. Others
  • 7.3. Latin America Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 7.3.1. Oncology
    • 7.3.2. Neurology
    • 7.3.3. Cardiology
    • 7.3.4. Infectious and Inflammatory Disease
    • 7.3.5. Others
  • 7.4. Latin America Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 7.4.1. Pharmaceutical and Biotechnology Companies
    • 7.4.2. Emerging Radiopharmaceutical Biotechs
    • 7.4.3. Academic and Research Institutes
    • 7.4.4. Government and Nuclear Research Organizations
  • 7.5. Latin America Radiopharmaceutical Preclinical CRO Market Outlook, by Country and Subregion, 2026-2033
    • 7.5.1. Brazil Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 7.5.2. Brazil Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 7.5.3. Brazil Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 7.5.4. Brazil Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 7.5.5. Argentina Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 7.5.6. Argentina Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 7.5.7. Argentina Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 7.5.8. Argentina Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 7.5.9. Mexico Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 7.5.10. Mexico Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 7.5.11. Mexico Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 7.5.12. Mexico Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033

8. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook 2026-2033

  • 8.1. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, Value (US$ Billion), 2026-2033
    • 8.1.1. Radiolabeling and Radiochemistry
    • 8.1.2. Preclinical Imaging
    • 8.1.3. In Vivo Pharmacokinetics and Biodistribution
    • 8.1.4. Dosimetry and Radiation Safety
    • 8.1.5. Toxicology and IND-Enabling Studies
  • 8.2. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, Value (US$ Billion), 2026-2033
    • 8.2.1. Beta Emitters
    • 8.2.2. Alpha Emitters
    • 8.2.3. Diagnostic Positron and Gamma Emitters
    • 8.2.4. Others
  • 8.3. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Application, Value (US$ Billion), 2026-2033
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Cardiology
    • 8.3.4. Infectious and Inflammatory Disease
    • 8.3.5. Others
  • 8.4. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook, by End User, Value (US$ Billion), 2026-2033
    • 8.4.1. Pharmaceutical and Biotechnology Companies
    • 8.4.2. Emerging Radiopharmaceutical Biotechs
    • 8.4.3. Academic and Research Institutes
    • 8.4.4. Government and Nuclear Research Organizations
  • 8.5. Middle East & Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Country and Subregion, 2026-2033
    • 8.5.1. Saudi Arabia Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.2. Saudi Arabia Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.3. Saudi Arabia Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.4. Saudi Arabia Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 8.5.5. United Arab Emirates Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.6. United Arab Emirates Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.7. United Arab Emirates Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.8. United Arab Emirates Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 8.5.9. Israel Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.10. Israel Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.11. Israel Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.12. Israel Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 8.5.13. Turkey Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.14. Turkey Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.15. Turkey Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.16. Turkey Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 8.5.17. South Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.18. South Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.19. South Africa Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.20. South Africa Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033
    • 8.5.21. Gulf states Radiopharmaceutical Preclinical CRO Market Outlook, by Service Type, 2026-2033
    • 8.5.22. Gulf states Radiopharmaceutical Preclinical CRO Market Outlook, by Isotope Type, 2026-2033
    • 8.5.23. Gulf states Radiopharmaceutical Preclinical CRO Market Outlook, by Application, 2026-2033
    • 8.5.24. Gulf states Radiopharmaceutical Preclinical CRO Market Outlook, by End User, 2026-2033

9. Competitive Landscape

  • 9.1. Competitive Positioning and Strategies
  • 9.2. Company Profiles
    • 9.2.1. Charles River Laboratories
    • 9.2.2. Labcorp
    • 9.2.3. Inotiv
    • 9.2.4. Invicro
    • 9.2.5. Evotec
    • 9.2.6. Pharmaron
    • 9.2.7. WuXi AppTec
    • 9.2.8. Eckert & Ziegler
    • 9.2.9. Crown Bioscience
    • 9.2.10. SOFIE
    • 9.2.11. Symeres
    • 9.2.12. Selvita
    • 9.2.13. Nuvisan
    • 9.2.14. Shin Nippon Biomedical Laboratories
    • 9.2.15. ABX advanced biochemical compounds
    • 9.2.16. Molecular Targeting Technologies
    • 9.2.17. Nuclear Research and Consultancy Group
    • 9.2.18. Quotient Sciences
    • 9.2.19. Nucleus RadioPharma
    • 9.2.20. ITM Isotope Technologies Munich

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!